Skip to main content

Table 3 Starting days and crude event rates for different macrolides and fluoroquinolones

From: Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial

Macrolides Azithromycin Clarithromycin Erythromycin
Patients with antibiotic any time during admission 207 250 277
Starting day of antibiotic during admission¶ 1 (0–2) 0 (0–1) 0 (0–0)
Percentage starting antibiotic intravenously § 263 (94.9%)
Cardiac event a) Any type 11 (5.3%) 18 (7.2%) 31 (11.2%)
b) Heart failure 9 (4.3%) 14 (5.6%) 26 (9.4%)
c) Arrhythmia 6 (2.9%) 5 (2%) 10 (3.6%)
Fluoroquinolones Ciprofloxacin Levofloxacin Moxifloxacin
Patients with antibiotic any time during admission 234* 194 566
Starting day of antibiotic during admission¶ 1 (0–3) 0 (0–0) 0 (0–0)
Percentage starting antibiotic intravenously 76 (32.5%) 111 (57.2%) 394 (69.6%)
Cardiac event a) Any type 9 (3.8%) 5 (2.6%) 23 (4.1%)
b) Heart failure 9 (3.8%) 3 (1.5%) 16 (2.8%)
c) Arrhythmia 5 (2.1%) 3 (1.5%) 11 (1.9%)
  1. Values are numbers (percentages) unless otherwise noted. ¶Median (interquartile range) *One patient received ofloxacin
  2. § Azithromycin and clarithromycin are not available for intravenous administration in the Netherlands